ABL1

Biomarkers

ABL1 is involved in the following curated biomarkers.

Name	Biomarker type	Propositions	Statements
BCR::ABL1	Rearrangement	1	1
BCR::ABL1	Rearrangement	14	36
ABL1 p.T315I	Somatic Variant	3	5

Therapeutic response

Precision oncology relationships for therapeutic response involving this gene.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	BCR::ABL1	Acute Lymphoid Leukemia	Cytarabine, Methotrexate, Ponatinib, Prednisone, Vincristine	FDA
Sensitivity (+)	ABL1 p.T315I, BCR::ABL1	Acute Lymphoid Leukemia	Ponatinib	FDA
Sensitivity (+)	ABL1 p.T315I	Chronic Myelogenous Leukemia	Ponatinib	FDA
Sensitivity (+)	ABL1 p.T315I	Chronic Myelogenous Leukemia	Ponatinib	HC
Sensitivity (+)	ABL1 p.T315I, BCR::ABL1	Acute Lymphoid Leukemia	Ponatinib	HC
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib	HC
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib	HC
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Imatinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Imatinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Imatinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Imatinib	FDA
Sensitivity (+)	BCR::ABL1	Acute Lymphoid Leukemia	Imatinib	FDA
Sensitivity (+)	BCR::ABL1	Acute Lymphoid Leukemia	Imatinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Imatinib	HC
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Imatinib	HC
Sensitivity (+)	BCR::ABL1	Acute Lymphoid Leukemia	Imatinib	HC
Sensitivity (+)	BCR::ABL1	Acute Lymphoid Leukemia	Imatinib	HC
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Nilotinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Nilotinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Nilotinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Nilotinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Nilotinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Nilotinib	FDA
Sensitivity (+)	BCR::ABL1, CD19 +	Acute Lymphoid Leukemia	Blinatumomab	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Dasatinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Dasatinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Dasatinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Dasatinib	FDA
Sensitivity (+)	BCR::ABL1	Acute Lymphoid Leukemia	Dasatinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Dasatinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Dasatinib	FDA
Sensitivity (+)	BCR::ABL1	Acute Lymphoid Leukemia	Dasatinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Asciminib	FDA
Sensitivity (+)	ABL1 p.T315I, BCR::ABL1	Chronic Myelogenous Leukemia	Asciminib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Asciminib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Asciminib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Asciminib	FDA